Eli Lilly halts COVID-19 antibody treatment trial over safety issues
Category: #headlines  | By Nikita Chaurasia  | Date: 2020-10-15 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Eli Lilly halts COVID-19 antibody treatment trial over safety issues

 

  • The announcement comes along the heels of a sudden spike in the number of coronavirus cases across U.S.
  • Eli Lilly’s shares dropped by about 3% after it halted the COVID-19 antibody trials.

Eli Lilly and Company, an American pharmaceutical company, has reportedly announced that it has paused its government sponsored COVID-19 antibody treatment trial over safety concerns. Sources close to the matter stated that the announcement comes along the heels of a sudden spike in the number of coronavirus cases across United States.

For the record, Eli Lilly’s COVID-19 antibody study will focus on the benefits of the therapy on various patients suffering from the novel coronavirus. Besides the potential antibody, each participant has reportedly also received an experimental drug called remdesivir which is commonly used to treat COVID-19 patients.

It is to be noted that the company had recently requested for an EUA (emergency use authorization) for its antibody LY-CoV555 from the U.S. Food & Drug Association (FDA). However, the exact safety concerns which halted the trials remain unclear, sources claimed.

Molly McCully, a spokesperson from Eli Lilly mentioned in a comment that the ACTIV-3 data safety monitoring board (DSMB) suggested the company to halt the trials. She further added that the Eli Lilly supported the decision made by the independent DSMB for the wellbeing of the study participants.

According to industry experts, such pauses during large scale clinical trials are not an uncommon instance and the decline in the volunteer’s health is not necessarily due to the vaccine or an experimental drug. In fact, such study halts enable scientific experts to review the data generated during the trials.

Eli Lilly’s shares dropped by about 3% after it halted the COVID-19 antibody trials, cited sources with relevant information.

In other news, another American pharmaceutical company, Johnson & Johnson, had reportedly paused its study for COVID-19 antibody candidate after one of the trial participants witnessed an unexpected illness.

Source- https://www.aljazeera.com/economy/2020/10/13/eli-lilly-pauses-covid-19-antibody-trial-due-to-safety-concern

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Fintech firm PayPal to shed around 2000 staff as global economy plummets

Fintech firm PayPal to shed around 2000 staff as global economy plummets

By Nikita Chaurasia

PayPal, the U.S.-based fintech giant, has reportedly announced that it will cut nearly 2000 jobs, approximately 7% of its workforce, as it turns the latest prominent tech company to shed staff in a bid to cut costs. The online payments provider cl...

EasyJet sees a rise in bookings as customers plan their next vacations

EasyJet sees a rise in bookings as customers plan their next vacations

By Nikita Chaurasia

British multinational low-cost airline group, EasyJet, has reported a record surge in bookings for the month of January as people prioritized their travel plans for the coming year. The news comes as airlines world over start to show signs that they&...

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

By Nikita Chaurasia

Dr. Reddy's Laboratories Ltd. and Cipla Ltd. surpassed Aurobindo Pharma to rank as the 2nd and 3rd largest drug manufacturers in India by sales in the three months that ended on September 30. This was the first change in the pecking order of the ...